Your browser doesn't support javascript.
Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK.
Banfill, K; Croxford, W; Fornacon-Wood, I; Wicks, K; Ahmad, S; Britten, A; Carson, C; Dorey, N; Hatton, M; Hiley, C; Thippu Jayaprakash, K; Jegannathen, A; Koh, P; Panakis, N; Peedell, C; Pope, A; Powell, C; Stilwell, C; Thomas, B; Toy, E; Wood, V; Yahya, S; Zhou, S Y; Price, G; Faivre-Finn, C.
  • Banfill K; The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK. Electronic address: kathryn.banfill@manchester.ac.uk.
  • Croxford W; The Christie NHS Foundation Trust, Manchester, UK.
  • Fornacon-Wood I; The University of Manchester, Manchester, UK.
  • Wicks K; The University of Manchester, Manchester, UK.
  • Ahmad S; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Britten A; Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
  • Carson C; The Northern Ireland Cancer Centre, Belfast, UK.
  • Dorey N; Torbay and South Devon NHS Foundation Trust, Torquay, UK.
  • Hatton M; Weston Park Hospital, Sheffield, UK.
  • Hiley C; University College London Hospitals, London, UK.
  • Thippu Jayaprakash K; Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Jegannathen A; University Hospitals North Midlands, Stoke-on-Trent, UK.
  • Koh P; Royal Wolverhampton NHS Trust, Wolverhampton, UK.
  • Panakis N; Oxford Universities NHS Trust, Oxford, UK.
  • Peedell C; The James Cook University Hospital, Middlesbrough, UK.
  • Pope A; Clatterbridge Cancer Centre, Bebington, UK.
  • Powell C; Velindre Cancer Centre, Cardiff, UK.
  • Stilwell C; Aberdeen Royal Infirmary, Aberdeen, UK.
  • Thomas B; Swansea Bay University Hospital, Swansea, UK.
  • Toy E; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Wood V; University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
  • Yahya S; University Hospitals Birmingham, Birmingham, UK.
  • Zhou SY; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Price G; The University of Manchester, Manchester, UK.
  • Faivre-Finn C; The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.
Clin Oncol (R Coll Radiol) ; 34(1): 19-27, 2022 01.
Article in English | MEDLINE | ID: covidwho-1487658
ABSTRACT

AIMS:

In response to the COVID-19 pandemic, guidelines on reduced fractionation for patients treated with curative-intent radiotherapy were published, aimed at reducing the number of hospital attendances and potential exposure of vulnerable patients to minimise the risk of COVID-19 infection. We describe the changes that took place in the management of patients with stage I-III lung cancer from April to October 2020. MATERIALS AND

METHODS:

Lung Radiotherapy during the COVID-19 Pandemic (COVID-RT Lung) is a prospective multicentre UK cohort study. The inclusion criteria were patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between 2nd April and 2nd October 2020. Patients who had had a change in their management and those who continued with standard management were included. Data on demographics, COVID-19 diagnosis, diagnostic work-up, radiotherapy and systemic treatment were collected and reported as counts and percentages. Patient characteristics associated with a change in treatment were analysed using multivariable binary logistic regression.

RESULTS:

In total, 1553 patients were included (median age 72 years, 49% female); 93 (12%) had a change to their diagnostic investigation and 528 (34%) had a change to their treatment from their centre's standard of care as a result of the COVID-19 pandemic. Age ≥70 years, male gender and stage III disease were associated with a change in treatment on multivariable analysis. Patients who had their treatment changed had a median of 15 fractions of radiotherapy compared with a median of 20 fractions in those who did not have their treatment changed. Low rates of COVID-19 infection were seen during or after radiotherapy, with only 21 patients (1.4%) developing the disease.

CONCLUSIONS:

The COVID-19 pandemic resulted in changes to patient treatment in line with national recommendations. The main change was an increase in hypofractionation. Further work is ongoing to analyse the impact of these changes on patient outcomes.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Clin Oncol (R Coll Radiol) Journal subject: Neoplasms Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Clin Oncol (R Coll Radiol) Journal subject: Neoplasms Year: 2022 Document Type: Article